Investor Overview

Stock Information
Loading data...

Shares outstanding

62,060,395 (as of 05/10/2024)

Press Releases
Jun 27, 2024

— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for...

Jun 11, 2024

-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive...

May 15, 2024

The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced...

Apr 18, 2024

-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in...

Mar 27, 2024

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel.

  • The U.S. contraceptive market was estimated at $8.3 billion as of 2022.
  • Every 1% market share of the 43.3 million women in our addressable market represents more than $450 million in net product sales for Evofem.
  • 2023 marked the third consecutive year of Phexxi net sales growth.  

Evofem intends to expand Phexxi's global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

On December 11, 2023, Evofem and Aditxt, Inc. (Nasdaq: ADTX) entered into the Agreement and Plan of Merger by and between the companies (the "Merger Agreement"). On May 3, 2024, Evofem and Aditxt reinstated the Merger Agreement, as amended, and entered into the Fourth Amendment to the Agreement and Plan of Merger. The companies are working toward close in the second half of 2024.

Evofem believes the proposed Transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise.

The Company's common stock currently trades on the OTCQB Venture Market under the ticker symbol "EVFM".

Featured Event
Thursday, May 16, 2024

Amy Raskopf, Evofem's SVP of Investor Relations, spoke with the MarketGems Podcast. Listen in!

View All

Latest Financial Results

Q4 and fiscal year ended December 31, 2023

Earnings Release
10-K Filing